Breaking News

Bayer To Establish Manufacturing Capacity in Germany

To support factor VIII (rFVIII) hemophilia products in Phase III development

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bayer HealthCare is investing more than €500 million to establish manufacturing capacity for recombinant factor VIII (rFVIII) hemophilia products that are currently in development at its sites in Wuppertal and Leverkusen, Germany. The company’s two investigational therapies for hemophilia A are currently in Phase III development. Bayer’s approved hemophilia A product is manufactured exclusively in Berkeley, CA. The additional supply source in Germany will help prepare for production of the...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters